Nature Publishing Group

SHERPA: Yellow

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Levine
    Levine
  3. Diamond
    Diamond
  4. Dogan
    Dogan
  5. Gonen
    Gonen
  6. Arcila
    Arcila
  7. Petrova-Drus
    Petrova-Drus
  8. Rampal
    Rampal
  9. Tallman
    Tallman
  10. Yabe
    Yabe

Groups

  1. Center for Hematologic Malignancies (83)
  2. Department of Medicine (83)
  3. Executive Committee, Center for Hematologic Malignancies (83)
  4. GSK Faculty (83)
  5. Hematologic Malignancies, Division of (83)
  6. Tow Center for Developmental Oncology (TCDO) (83)
  7. Adult Leukemia (44)
  8. Sloan Kettering Institute Postdocs (41)
  9. Center for Molecular Imaging and Biotechnology (CMIB) (40)
  10. Human Oncology and Pathogenesis Program (39)
Search Within
  1. "Omar Abdel-Wahab"
Formats
  1. Journal Article (67)
  2. Editorial (5)
  3. Meeting Abstract (5)
  4. Research Letter (5)
  5. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (83)
  2. Department of Medicine (83)
  3. Executive Committee, Center for Hematologic Malignancies (83)
  4. GSK Faculty (83)
  5. Hematologic Malignancies, Division of (83)
  6. Tow Center for Developmental Oncology (TCDO) (83)

More Groups

People
  1. Omar Abdel-Wahab (83)
  2. Ross Levine (34)
  3. Benjamin Durham (16)
  4. Jay Patel (11)
  5. Alessandro Pastore (9)
  6. Stanley Lee (8)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (5)
  4. 2022 (8)
  5. 2021 (6)
  6. 2020 (4)

More Years

Publications
  1. Leukemia (29)
  2. Nature (12)
  3. Nature Medicine (9)
  4. Nature Communications (6)
  5. Laboratory Investigation (5)
  6. Nature Genetics (4)

More Publications

Results (83)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
    Research Letter

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A.; Sallman, D.; Patel, M.; Stevens, D.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms
    Correspondence

    Salmon-Divon, M.; Meyuchas, R.; Shpilberg, O.; Okon, E.; Benhamida, J.; Yabe, M.; Petrova-Drus, K.; Zvida-Bloch, T.; Basood, M.; Mazor, R.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Mapping genotypes to chromatin accessibility profiles in single cells
    Journal Article

    Izzo, F.; Myers, R. M.; Ganesan, S.; Mekerishvili, L.; Kottapalli, S.; Prieto, T.; Eton, E. O.; Botella, T.; Dunbar, A. J.; Bowman, R. L.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis
    Research Letter

    Sui, P.; Ge, G.; Chen, S.; Bai, J.; Rubalcava, I. P.; Yang, H.; Guo, Y.; Zhang, P.; Li, Y.; Medina, E. A.; more...
    Leukemia (2024)

    Fulltext@MSK | Save
  • E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Research Letter

    Bewersdorf, J. P.; Stahl, M.; Taylor, J.; Mi, X.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Lu, S. X.; Bourcier, J.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state
    Journal Article

    Xiao, M.; Kondo, S.; Nomura, M.; Kato, S.; Nishimura, K.; Zang, W.; Zhang, Y.; Akashi, T.; Viny, A.; Shigehiro, T.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
    Journal Article

    Ptashkin, R. N.; Ewalt, M. D.; Jayakumaran, G.; Kiecka, I.; Bowman, A. S.; Yao, J. J.; Casanova, J.; Lin, Y. T. D.; Petrova-Drus, K.; Mohanty, A. S.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
    Research Letter

    Diamond, E. L.; Francis, J. H.; Lacouture, M. E.; Rotemberg, V.; Yabe, M.; Petrova-Drus, K.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
    Leukemia (2023)

    Fulltext@MSK | Save
  • SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
    Journal Article

    Willekens, C.; Laplane, L.; Dagher, T.; Benlabiod, C.; Papadopoulos, N.; Lacout, C.; Rameau, P.; Catelain, C.; Alfaro, A.; Edmond, V.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Finding consistency in classifications of myeloid neoplasms: A perspective on behalf of the International Workshop for Myelodysplastic Syndromes
    Editorial

    Zeidan, A. M.; Bewersdorf, J. P.; Buckstein, R.; Sekeres, M. A.; Steensma, D. P.; Platzbecker, U.; Loghavi, S.; Boultwood, J.; Bejar, R.; Bennett, J. M.; more...
    Leukemia (2022)

    Fulltext@MSK | Save